| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Leonard Angka | Q42415141 |
| P2093 | author name string | Michele Ardolino | |
| Rebecca C Auer | |||
| Oladunni Olanubi | |||
| Marisa Market | |||
| Juliana Ng | |||
| Andre B Martel | |||
| Dominique M Boucher | |||
| Donald Bastin | |||
| Gayashan Tennakoon | |||
| P2860 | cites work | SARS: systematic review of treatment effects | Q21144696 |
| Vitamin C for preventing and treating the common cold | Q24201652 | ||
| Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells | Q24314176 | ||
| Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains | Q24317666 | ||
| Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes | Q24328841 | ||
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 | ||
| Vitamins C and E: beneficial effects from a mechanistic perspective | Q24617202 | ||
| Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus | Q24632337 | ||
| Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b) | Q24646967 | ||
| Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control | Q26747397 | ||
| Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory? | Q26776114 | ||
| Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia | Q26991666 | ||
| Innate immune recognition | Q27860721 | ||
| Coronavirus as a possible cause of severe acute respiratory syndrome | Q28200848 | ||
| Indomethacin has a potent antiviral activity against SARS coronavirus | Q28219047 | ||
| Type I interferons in infectious disease | Q28255842 | ||
| Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients | Q96033597 | ||
| Immunology of COVID-19: Current State of the Science | Q96156437 | ||
| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study | Q96163179 | ||
| A single-cell atlas of the peripheral immune response in patients with severe COVID-19 | Q96230984 | ||
| Type III interferons disrupt the lung epithelial barrier upon viral recognition | Q96302241 | ||
| Type I and III interferons disrupt lung epithelial repair during recovery from viral infection | Q96302254 | ||
| Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients | Q96612547 | ||
| HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C | Q28263511 | ||
| Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro | Q28387755 | ||
| Innate or adaptive immunity? The example of natural killer cells | Q29615106 | ||
| NK cell recognition | Q29615107 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China | Q29618055 | ||
| Infections in Cancer Patients with Solid Tumors: A Review | Q30238576 | ||
| A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes | Q30524109 | ||
| A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice | Q33269158 | ||
| Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study | Q33409373 | ||
| Hematologic, hepatic, and renal function changes in hospitalized patients with Middle East respiratory syndrome coronavirus | Q33441395 | ||
| Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection | Q33614444 | ||
| Ly49C-dependent control of MCMV Infection by NK cells is cis-regulated by MHC Class I molecules | Q33686132 | ||
| Structure, Function, and Evolution of Coronavirus Spike Proteins | Q33760875 | ||
| The effect of ageing on human lymphocyte subsets: comparison of males and females | Q33804295 | ||
| An interferon-gamma-related cytokine storm in SARS patients | Q33844674 | ||
| Multiple organ infection and the pathogenesis of SARS. | Q33988914 | ||
| Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus | Q34193942 | ||
| Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking | Q34243319 | ||
| Impact of aging on viral infections | Q34388458 | ||
| Phenotype and functions of natural killer cells in critically-ill septic patients | Q34510379 | ||
| Natural killer cell memory in infection, inflammation and cancer | Q34510646 | ||
| Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | Q34539541 | ||
| Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells | Q34658319 | ||
| Novel drugs targeting Toll-like receptors for antiviral therapy | Q34999938 | ||
| CpG DNA as a vaccine adjuvant. | Q35025722 | ||
| Natural killer cell responses to viral infection. | Q35082268 | ||
| Cytokine therapy reverses NK cell anergy in MHC-deficient tumors | Q35140125 | ||
| T cell exhaustion during persistent viral infections | Q35582265 | ||
| In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice | Q35760429 | ||
| Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection | Q35826605 | ||
| CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. | Q35834087 | ||
| Mice susceptible to SARS coronavirus | Q35880913 | ||
| Innate immunity in the lungs | Q36328672 | ||
| Human NK cell lytic granules and regulation of their exocytosis | Q36386541 | ||
| Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide | Q40349551 | ||
| IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. | Q40577440 | ||
| Immune Modulation with Thymosin Alpha 1 Treatment | Q40602282 | ||
| Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection | Q40665233 | ||
| Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection | Q40783682 | ||
| A new mechanism of vitamin C effects on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed mice. | Q41467378 | ||
| Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. | Q42152380 | ||
| Distinct Effects of Dexamethasone on Human Natural Killer Cell Responses Dependent on Cytokines | Q42291773 | ||
| DNAM-1: would the real natural killer cell please stand up! | Q42558119 | ||
| Detection of severe acute respiratory syndrome-associated coronavirus in pneumocytes of the lung | Q42624714 | ||
| Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells | Q42742439 | ||
| Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. | Q42844863 | ||
| Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells | Q43543239 | ||
| Vitamin C deficiency in elderly hospitalized patients | Q43787058 | ||
| Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice | Q44412125 | ||
| NK cells exacerbate the pathology of influenza virus infection in mice | Q44764762 | ||
| Corticosteroid Therapy for Critically Ill Patients with the Middle East Respiratory Syndrome | Q45073537 | ||
| Critical role of natural killer cells in lung immunopathology during influenza infection in mice. | Q45195586 | ||
| Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice | Q45354132 | ||
| A new virus isolated from the human respiratory tract | Q45825116 | ||
| The functional role of natural killer cells early in clinical sepsis | Q45833437 | ||
| Vitamin C and Immune Function | Q46269475 | ||
| ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). | Q46280873 | ||
| Massive and long-lasting decrease in vitamin C plasma levels as a consequence of extracorporeal circulation | Q46919039 | ||
| Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System. | Q47140967 | ||
| Association Between Natural Killer Cell Activity and Colorectal Cancer in High-Risk Subjects Undergoing Colonoscopy | Q47342903 | ||
| Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients | Q47371541 | ||
| BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity | Q47555324 | ||
| The biology of natural killer cells during sepsis. | Q47602497 | ||
| Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases | Q47863910 | ||
| The role of the interleukin-1 family in trained immunity | Q48105533 | ||
| The potential and promise of IL-15 in immuno-oncogenic therapies. | Q49216382 | ||
| Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? NK Cell Memory and Immunization Strategies against Infectious Diseases and Cancer. | Q49645475 | ||
| Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore | Q51652773 | ||
| Lung pathology of fatal severe acute respiratory syndrome. | Q51670647 | ||
| Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial. | Q52584419 | ||
| FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. | Q52603828 | ||
| ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. | Q52720857 | ||
| Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. | Q52805676 | ||
| Introduction to checkpoint inhibitors and cancer immunotherapy. | Q54657348 | ||
| NKG2D: A Master Regulator of Immune Cell Responsiveness. | Q55216305 | ||
| Severe herpesvirus infections in an adolescent without natural killer cells | Q55984308 | ||
| Severe acute respiratory syndrome | Q56775278 | ||
| Fundamental Mechanisms of Immune Checkpoint Blockade Therapy | Q56889286 | ||
| Natural killer cell specificity for viral infections | Q56966491 | ||
| Cytokines in clinical cancer immunotherapy | Q58561585 | ||
| MERS coronavirus outbreak: Implications for emerging viral infections | Q58595060 | ||
| Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity | Q58782404 | ||
| Natural Killer Cells: Development, Maturation, and Clinical Utilization | Q58785734 | ||
| Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells | Q60302404 | ||
| Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant | Q60958294 | ||
| Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome | Q61911602 | ||
| The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis | Q64111046 | ||
| Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export | Q64124573 | ||
| Circulating growth/differentiation factor 15 is associated with human CD56bright natural killer cell dysfunction and nosocomial infection in severe systemic inflammation. | Q64974281 | ||
| Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. | Q64987872 | ||
| Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis. | Q64989105 | ||
| Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. | Q64997781 | ||
| Effects of corticosteroids on natural killer cell activity in systemic lupus erythematosus | Q71236718 | ||
| Thymosin alpha 1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies: preliminary results | Q72131537 | ||
| Effects of a "new" human respiratory virus in volunteers | Q72267375 | ||
| Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase-C | Q73567942 | ||
| Treatment of SARS with human interferons | Q73738906 | ||
| Changes in the expression of surface receptors on lymphocyte subsets in the elderly: quantitative flow cytometric analysis | Q73851823 | ||
| Expression of IL-15 in inflammatory pulmonary diseases | Q77347934 | ||
| Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection | Q78346749 | ||
| Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells | Q79327742 | ||
| The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome | Q79916879 | ||
| Characteristics of NK cell migration early after vaccinia infection | Q81008951 | ||
| [Dynamics of peripheral blood B lymphocytes and natural killer cells in patients with severe acute respiratory syndrome] | Q81037327 | ||
| Bovine coronavirus associated syndromes | Q82711829 | ||
| Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia | Q84108313 | ||
| Race to find COVID-19 treatments accelerates | Q90689550 | ||
| Innate Immune Evasion by Human Respiratory RNA Viruses | Q90697417 | ||
| Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study | Q90720676 | ||
| The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China | Q90720693 | ||
| Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China | Q90731609 | ||
| Human NK Cells and Herpesviruses: Mechanisms of Recognition, Response and Adaptation | Q90860927 | ||
| The Diverse Function of PD-1/PD-L Pathway Beyond Cancer | Q90860971 | ||
| NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors | Q91079924 | ||
| Diagnosis of Feline Infectious Peritonitis: A Review of the Current Literature | Q91299485 | ||
| Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery | Q91309605 | ||
| Cytokine Release Syndrome: Current Perspectives | Q91388495 | ||
| First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab | Q91533817 | ||
| Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection | Q91537559 | ||
| First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia | Q91562917 | ||
| CAR-NK for tumor immunotherapy: Clinical transformation and future prospects | Q91607137 | ||
| COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? | Q91638688 | ||
| Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) | Q91719745 | ||
| Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb®) in the management of septic shock: A retrospective observational study | Q92197510 | ||
| How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review | Q92331110 | ||
| NK cells for cancer immunotherapy | Q92453577 | ||
| Influenza A Virus Infection Induces Hyperresponsiveness in Human Lung Tissue-Resident and Peripheral Blood NK Cells | Q92479237 | ||
| Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System | Q92511392 | ||
| Training the trainable cells of the immune system and beyond | Q92564884 | ||
| Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation | Q92616859 | ||
| Killers 2.0: NK cell therapies at the forefront of cancer control | Q93071035 | ||
| Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure | Q93153123 | ||
| Shared and Distinct Functions of Type I and Type III Interferons | Q93158322 | ||
| GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts | Q93336074 | ||
| The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice | Q94148699 | ||
| The trinity of COVID-19: immunity, inflammation and intervention | Q94452368 | ||
| Considering BCG vaccination to reduce the impact of COVID-19 | Q94487166 | ||
| Obesity could shift severe COVID-19 disease to younger ages | Q94538338 | ||
| Does COVID-19 Spread Through Droplets Alone? | Q94547145 | ||
| NKG2A and COVID-19: another brick in the wall | Q94550926 | ||
| BCG-induced trained immunity: can it offer protection against COVID-19? | Q94562725 | ||
| HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19 | Q94568423 | ||
| BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis | Q94590852 | ||
| Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages | Q94591662 | ||
| Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 | Q94600823 | ||
| SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults | Q94654358 | ||
| Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial | Q94657383 | ||
| Multiorgan and Renal Tropism of SARS-CoV-2 | Q94659963 | ||
| The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection | Q94672292 | ||
| COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease | Q94930355 | ||
| COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons | Q94956600 | ||
| Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection | Q95295198 | ||
| Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions | Q95604176 | ||
| The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? | Q95637131 | ||
| Pathogenesis and transmission of SARS-CoV-2 in golden hamsters | Q95644306 | ||
| Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent | Q95941697 | ||
| Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury | Q84649317 | ||
| IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cells | Q85790782 | ||
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 | Q86729469 | ||
| Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding | Q86735535 | ||
| Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study | Q87191917 | ||
| Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks | Q87461284 | ||
| High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa | Q87461399 | ||
| Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV | Q87461558 | ||
| Origin and evolution of pathogenic coronaviruses | Q87747946 | ||
| Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? | Q87812699 | ||
| Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target | Q88291889 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| Vitamin C for the treatment of sepsis: The scientific rationale | Q88442662 | ||
| Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors | Q89548367 | ||
| Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China | Q89746683 | ||
| The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? | Q89840059 | ||
| Natural killer cells as an initial defense against pathogens | Q36502291 | ||
| Natural killer cells act as rheostats modulating antiviral T cells | Q36517134 | ||
| SARS coronavirus and innate immunity | Q36539000 | ||
| Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. | Q36577616 | ||
| Type I interferons in viral control and immune regulation | Q36767643 | ||
| Keeping NK cells in highly regulated antiviral warfare | Q36805101 | ||
| The trafficking of natural killer cells | Q36990612 | ||
| Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice | Q37010921 | ||
| Cytokine-induced memory-like natural killer cells | Q37100910 | ||
| Natural killer cells in immunodefense against infective agents | Q37178929 | ||
| Vitamin C in disease prevention and cure: an overview | Q37199413 | ||
| Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. | Q37269093 | ||
| Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection | Q37273319 | ||
| Expansion of highly cytotoxic human natural killer cells for cancer cell therapy | Q37277554 | ||
| Innate immunity to virus infection. | Q37361448 | ||
| BCG-induced trained immunity in NK cells: Role for non-specific protection to infection | Q37374103 | ||
| Controlling natural killer cell responses: integration of signals for activation and inhibition | Q37404156 | ||
| Role of vitamin C in the function of the vascular endothelium | Q37406657 | ||
| Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection | Q37513066 | ||
| Natural killer cell deficiency | Q37567421 | ||
| Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses. | Q37723794 | ||
| Cytokine regulation of natural killer cell effector functions | Q37771915 | ||
| A cluster of cases of severe acute respiratory syndrome in Hong Kong. | Q37869740 | ||
| The role of natural killer cells in sepsis | Q37883097 | ||
| Control of human viral infections by natural killer cells | Q38072477 | ||
| From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses | Q38135197 | ||
| TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals | Q38173691 | ||
| NK cell self tolerance, responsiveness and missing self recognition | Q38196030 | ||
| NK cells and interferons. | Q38274574 | ||
| Natural killer cells: In health and disease | Q38311625 | ||
| NKp44 and Natural Cytotoxicity Receptors as Damage-Associated Molecular Pattern Recognition Receptors | Q38362633 | ||
| Middle East respiratory syndrome and severe acute respiratory syndrome | Q38725989 | ||
| Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses | Q38787797 | ||
| Trained immunity: A program of innate immune memory in health and disease. | Q38814347 | ||
| Molecular Evolution of Human Coronavirus Genomes. | Q38981548 | ||
| Type I Interferons and Natural Killer Cell Regulation in Cancer | Q39241784 | ||
| Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology | Q39279748 | ||
| Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69-CD56dim cells | Q39349959 | ||
| Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients | Q39959987 | ||
| Developmental and Functional Control of Natural Killer Cells by Cytokines | Q40086298 | ||
| Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness | Q40198041 | ||
| Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia | Q40200316 | ||
| About Training and Memory: NK-Cell Adaptation to Viral Infections | Q40326820 | ||
| NK Cell-Based Immune Checkpoint Inhibition | Q89965774 | ||
| NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines | Q90021348 | ||
| NK Cell Dysfunction and Checkpoint Immunotherapy | Q90265781 | ||
| Dysregulation of Natural Killer Cells in Obesity | Q90278648 | ||
| Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion | Q90286527 | ||
| COVID-19: consider cytokine storm syndromes and immunosuppression | Q90464964 | ||
| Functional exhaustion of antiviral lymphocytes in COVID-19 patients | Q90589856 | ||
| COVID-19 infection and rheumatoid arthritis: Faraway, so close! | Q90602641 | ||
| Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis | Q90603171 | ||
| Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic | Q90648520 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | immunotherapy | Q1427096 |
| COVID-19 | Q84263196 | ||
| P304 | page(s) | 1512 | |
| P577 | publication date | 2020-06-23 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies | |
| P478 | volume | 11 |
| Q99711258 | Harnessing Memory NK Cell to Protect Against COVID-19 |
| Q103009676 | JAK-STAT pathway inhibition and their implications in COVID-19 therapy |
| Q103732534 | Review of registered clinical trials for the treatment of COVID-19 |
| Q98783374 | SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway |
| Q100517030 | Whither immunity? The search for effective, durable immunity to coronavirus disease 2019 (COVID-19) |
Search more.